Daré Bioscience’s One-Time Bacterial Vaginosis Treatment Scores FDA Approval
The FDA has approved Daré Bioscience Inc (NASDAQ:DARE) Xaciato (DARE-BV1) to treat bacterial vaginosis. Xaciato is a thermosetting bioadhesive hydrogel containing…
Watching Dare Bioscience Shares; Traders Circulate Seeking Alpha Blog Post From Contributor Biotechlab’s Blog Titled ‘$DARE (Daré Bioscience) Bacterial Vaginosis Drug PDUFA Target Action Date Is December 7, 2021. $10.00 Price Target!’
https://seekingalpha.com/instablog/2694641-biotechlab/5672219-dare-dare-bioscience-bacterial-vaginosis-drug-pdufa-target-action-date-is-december-7-2021
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours:
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Dare Bioscience Q3 EPS $(0.18) Misses $(0.13) Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 25 percent increase over losses of $(0.24) per share from
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Geovax Labs (NASDAQ:GOVX) shares rose 46.37% to $6.06 during Tuesday's after-market session. This security traded at a volume of 1.9 million shares come close, making up 75.3% of its average volume over the last 100 days. The company's market cap stands at $38.3 million.
Dare Bioscience Reports Initiation Of Phase 1/2 Study Of DARE-VVA1 For Treatment Of Vulvar, Vaginal Atrophy
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal tamoxifen product being
Dare Bioscience Q2 EPS $(0.18) Misses $(0.16) Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 33.33 percent increase over losses of $(0.27) per share from